{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:51:52Z","timestamp":1775328712235,"version":"3.50.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Researchers have demonstrated that the combined use of taxanes and chemotherapy drugs, especially paclitaxel-based treatment, appeared to clinically benefit on advanced triple negative breast cancer (TNBC). This meta-analysis aims to obtain the existent evidence on efficacy and safety for taxanes-based combination therapy to treat advanced TNBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From 1991 to June 2022, seven databases (PubMed, Web of Science, Cochrane Library, Embase VIP, Wanfang, and CNKI databases) were comprehensively searched with no restricted language and region. The included randomized controlled trials (RCTs) compared taxanes-based combination therapy versus taxanes or other chemotherapy drugs. Statistical analysis was conducted using random-effect model, and the quality of RCTs was assessed using the tool of Cochrane Collaboration risk of bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six RCTs with a total of 8,236 advanced TNBC patients were included. Compared with taxanes monotherapy, taxanes-based combination therapy significantly prolonged progression-free survival (HR=0.79, 95%CI=0.74\u20130.83, I<jats:sup>2<\/jats:sup>= 0.0%, <jats:italic>p<\/jats:italic>=0.000) and overall survival (HR=0.88, 95%CI=0.82\u20130.94, I<jats:sup>2<\/jats:sup>= 9.3%, <jats:italic>p<\/jats:italic>=0.000) and increased the risk of vomiting (RR=1.26, 95%CI=1.07\u20131.48) and diarrhea (RR=1.82, 95%CI=1.22\u20132.70, I<jats:sup>2<\/jats:sup>= 90.3%, <jats:italic>p<\/jats:italic>=0.003). No statistical differences were observed in complete response rate (CRR), objective response rate (ORR), disease control rate (DCR), and progressive disease (PD) indexes (CRR: RR=1.38, 95%CI=0.96\u20131.99; ORR: RR=1.20, 95%CI=0.73\u20131.98; DCR: RR=1.09, 95%CI=1.00\u20131.19; PD: RR=0.70, 95%CI=0.47\u20131.04). Compared with other chemotherapy drugs, taxanes <jats:italic>plus<\/jats:italic> other chemotherapy drugs significantly reduced the incidence of vomiting (RR=0.60, 95%CI=0.44\u20130.84, I<jats:sup>2<\/jats:sup>= 12.3%, <jats:italic>p<\/jats:italic>=0.002) and neutropenia (RR=0.58, 95%CI=0.35\u20130.96, I<jats:sup>2<\/jats:sup>= 73.0%, <jats:italic>p<\/jats:italic>=0.036) during the treatment period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Taxanes-based combination therapy is evidently effective and well-tolerated in advanced TNBC, indicating that it might be a recommended option for treating advanced TNBC patients to some extent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD42022337802.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.972767","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T06:44:10Z","timestamp":1661928250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Qionglian","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zubing","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.772615","article-title":"Tumor-associated macrophages: Key players in triple-negative breast cancer","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/000313481808400636","article-title":"Triple-negative breast cancer: A comparison of race and survival","volume":"84","author":"Doepker Mp Fau-Holt","year":"2018","journal-title":"Am Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20200224-00122","article-title":"Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients","volume":"42","author":"Ou","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-2624","article-title":"Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer","volume":"10","author":"Tan","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: Activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist Update"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2613","article-title":"And drug administration approval overview in metastatic breast cancer","volume":"30","author":"Cortazar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86105","article-title":"The role of taxanes in triple-negative breast cancer: Literature review","volume":"9","author":"Mustacchi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001756","article-title":"Liver metastasis of a triple-negative breast cancer and complete remission for 5 years after treatment with combined Bevacizumab\/Paclitaxel\/Carboplatin: Case report and review of the literature","volume":"94","author":"Ogata","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy201","article-title":"Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: Results from the TnAcity trial","volume":"29","author":"Yardley","year":"2018","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.504","article-title":"Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses","volume":"111","author":"Brodowicz","year":"2014","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): A randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012415","article-title":"Association of metabolic syndrome and its components with risk of stroke recurrence and mortality: A meta-analysis","volume":"97","author":"Zhang","year":"2021","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS1104","article-title":"IMpassion130: A phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC)","volume":"34","author":"Emens","year":"2016","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/15387445.SABCS17-P5-21-01","article-title":"Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I","volume":"78","author":"Brufsky","year":"2018","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01295-y","article-title":"Atezolizumab (in combination with nab-paclitaxel): A review in advanced triple-negative breast cancer","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14217","article-title":"Eribulin regresses a cisplatinum-resistant rare-type triple-negative matrix-producing breast carcinoma patient-derived orthotopic xenograft mouse model","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Anticancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5603\/NJO.2014.0053","article-title":"Bevacizumab in the 1st line treatment of triple negative metastatic breast cancer patient-case report and review of the literature","volume":"64","author":"Badora-Rybicka","year":"2014","journal-title":"Nowotwory"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0162","article-title":"Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4285-6","article-title":"TITAN: Phase III study of Doxorubicin\/Cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer","volume":"164","author":"Yardley","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1014-9","article-title":"Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours","volume":"65","author":"Yamamoto","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1195-6","article-title":"Erratum to: 'Phase II\/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus Gemcitabine\/Carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (The TnAcity study): Study protocol for a randomized controlled trial","volume":"17","author":"Yardley","year":"2016","journal-title":"Trials"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyg093","article-title":"Measuring response in solid tumors: Comparison of RECIST and WHO response criteria","volume":"33","author":"Park","year":"2003","journal-title":"Jpn J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.01.003","article-title":"Efficacy of biological agents in metastatic triple-negative breast cancer","volume":"40","author":"Bramati","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181bdc2e0","article-title":"Overall survival: Still the gold standard: Why overall sSurvival remains the definitive end point in cancer clinical trials","volume":"15","author":"Driscoll","year":"2009","journal-title":"Cancer J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.6315","article-title":"Response rate as a regulatory end point in single-arm studies of advanced solid tumors","volume":"2","author":"Oxnard","year":"2016","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition","volume":"191","author":"Lamm","year":"2014","journal-title":"J Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/pubmed\/fdac036","article-title":"Strengthening systematic reviews in public health: Guidance in the cochrane handbook for systematic reviews of interventions, 2nd edition","author":"Cumpston","year":"2022","journal-title":"J Public Health (Oxf)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2780","article-title":"TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer","volume":"21","author":"Forero-Torres","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.13558\/j.cnki.issn1672-3686.2014.06.007","article-title":"Reseach of paclitaxel liposome combined with carboplatin in the treating metastatic triple negative breast cancer","volume":"15","author":"Qu","year":"2014","journal-title":"Med Innovation China"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-4659.2018.12.1613","article-title":"Clinical study on vinorelbine combined with cisplatin vs docetaxel combined with cisplatin in first-line treatment of advanced triple negative breast cancer","volume":"25","author":"He","year":"2018","journal-title":"Clin Med Eng"},{"key":"B44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) plus nab-paclitaxel (Pab-p) vs placebo plus nab-p in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)","volume":"30","author":"Schmid","year":"2018","journal-title":"Ann Oncol"},{"key":"B45","article-title":"Analysis of efficacy of paclitaxel combined with carboplatin in treatment of advanced triple negative breast cancer","volume":"15","author":"Zhao","year":"2018","journal-title":"Med Innovation China"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0059","article-title":"IMpassion132 phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer","volume":"15","author":"Cortes","year":"2019","journal-title":"Future Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz418","article-title":"Subgroup analysis of IMpassion1 30: Atezolizumab+Nab-paclitaxel (nab-p) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries","volume":"30","author":"Iwata","year":"2019","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.12.008","article-title":"Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer-a phase II trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib","volume":"19","author":"Symonds","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-614x.2019.35.015","article-title":"Study on the effect of gemcitabine combined with cisplatin in the treatment of patients with triple negative advanced breast cancer","volume":"35","author":"Ye","year":"2019","journal-title":"Chin Community Doctors"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3545","article-title":"FDA Approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1","volume":"26","author":"Narayan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): Primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06143-45","article-title":"Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally Advanced\/Metastatic triple-negative breast cancer","volume":"189","author":"Dent","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B54","article-title":"Efficacy of the combination of abraxane and oxaliplatin in patients with advanced breast cancer and its effects on serum MUC1, CD44v6 and VEGF","volume":"20","author":"Duan","year":"2021","journal-title":"J Clin Exp Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: Biomarker evaluation of the IMpassion130 study","volume":"113","author":"Emens","year":"2021","journal-title":"Jnci-Journal Natl Cancer Inst"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06367-5","article-title":"A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)","volume":"190","author":"Goldstein","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B58","first-page":"7","article-title":"The value of paclitaxel combined with capecitabine regimen in patients with advanced triple negative breast cancer","author":"Li","year":"2021","journal-title":"Self Care"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-4721.2021.12.029","article-title":"Clinic effect and safety of SOX regimen in the treatment of advanced triple negative breast cancer","volume":"28","author":"Lu","year":"2021","journal-title":"China Modern Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally Advanced\/Metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000512200","article-title":"Carboplatin-cyclophosphamide or paclitaxel without or with bevacizumab as first-line treatment for metastatic triple-negative breast cancer (BOOG 2013-01)","volume":"16","author":"van Rossum","year":"2021","journal-title":"Breast Care (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.972767\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T06:44:29Z","timestamp":1661928269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.972767\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":61,"alternative-id":["10.3389\/fonc.2022.972767"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.972767","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"972767"}}